In a report released yesterday, Gena Wang from Barclays reiterated a Sell rating on Kodiak Sciences (KOD – Research Report), with a price target of $2.00. The company’s shares closed yesterday at $3.01.
Wang covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, PTC Therapeutics, and Mirati Therapeutics. According to TipRanks, Wang has an average return of 11.0% and a 43.92% success rate on recommended stocks.
Currently, the analyst consensus on Kodiak Sciences is a Moderate Sell with an average price target of $4.00.
See Insiders’ Hot Stocks on TipRanks >>
Based on Kodiak Sciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $70.78 million. In comparison, last year the company had a GAAP net loss of $95.71 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Kodiak Sciences, Inc. is a a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline include KSI-301 for wet AMD; KSI-301 for diabetic eye disease; KSI-501 for DME and uveitis; KSI-201 for resistant wet AMD; and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.
Read More on KOD:
